within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EJ02_Fedratinib;

model Fedratinib
  extends Pharmacolibrary.Drugs.ATC.L.L01EJ02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EJ02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fedratinib is an oral selective Janus kinase 2 (JAK2) inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post–polycythemia vera or post–essential thrombocythemia) myelofibrosis. It is currently approved by regulatory agencies such as the FDA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with myelofibrosis after repeated oral administration of 400 mg once daily.</p><h4>References</h4><ol><li><p>Ogasawara, K, et al., &amp; Krishna, G (2020). Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. <i>Cancer chemotherapy and pharmacology</i> 85(6) 1109–1117. DOI:<a href=\"https://doi.org/10.1007/s00280-020-04084-2\">10.1007/s00280-020-04084-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32449142/\">https://pubmed.ncbi.nlm.nih.gov/32449142</a></p></li><li><p>Ogasawara, K, et al., &amp; Krishna, G (2020). Excretion balance and pharmacokinetics following a single oral dose of [. <i>Cancer chemotherapy and pharmacology</i> 86(2) 307–314. DOI:<a href=\"https://doi.org/10.1007/s00280-020-04121-0\">10.1007/s00280-020-04121-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32748109/\">https://pubmed.ncbi.nlm.nih.gov/32748109</a></p></li><li><p>Ogasawara, K, et al., &amp; Krishna, G (2020). A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. <i>Cancer chemotherapy and pharmacology</i> 85(5) 995–1001. DOI:<a href=\"https://doi.org/10.1007/s00280-020-04074-4\">10.1007/s00280-020-04074-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32318809/\">https://pubmed.ncbi.nlm.nih.gov/32318809</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fedratinib;
